9:41 ●●● 5G
Managing a patient with elevated potassium?
Keeping them on RAASi therapy
Lokelma can help manage hyperkalemia so patients stay on guideline-directed RAAS inhibitor therapy instead of down-titrating or stopping it.
  • Supports RAASi continuation and optimization
  • Sustained potassium control with ongoing dosing
  • Especially relevant in CKD and heart failure
Get the RAASi-continuation guideRequest a rep visit
Dosing & titration
Lokelma has a correction phase and a maintenance phase, with onset of action within about one hour.
  • Correction: 10 g three times daily for up to 48 hours
  • Maintenance: 5 g once daily, titrate between 5–10 g
  • Onset of action within ~1 hour
Get the dosing guide
Which patients are right for Lokelma
Lokelma is for adults with hyperkalemia — most valuable where you want to preserve RAASi therapy.
  • CKD patients on RAASi with elevated potassium
  • Heart failure patients where RAASi is guideline-directed
  • Patients with recurrent hyperkalemia
Request a rep visit
Acute vs. chronic management
Lokelma is for ongoing management of hyperkalemia. It should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset.
  • Designed for chronic, ongoing potassium control
  • Not for emergent, life-threatening hyperkalemia
  • Pairs with RAASi optimization over time
Get the clinical overview
https://www.lokelma-hcp.com
Managing a patient with elevated potassium?
Keeping them on RAASi therapy
Lokelma can help manage hyperkalemia so patients stay on guideline-directed RAAS inhibitor therapy instead of down-titrating or stopping it.
  • Supports RAASi continuation and optimization
  • Sustained potassium control with ongoing dosing
  • Especially relevant in CKD and heart failure
Get the RAASi-continuation guideRequest a rep visit
Dosing & titration
Lokelma has a correction phase and a maintenance phase, with onset of action within about one hour.
  • Correction: 10 g three times daily for up to 48 hours
  • Maintenance: 5 g once daily, titrate between 5–10 g
  • Onset of action within ~1 hour
Get the dosing guide
Which patients are right for Lokelma
Lokelma is for adults with hyperkalemia — most valuable where you want to preserve RAASi therapy.
  • CKD patients on RAASi with elevated potassium
  • Heart failure patients where RAASi is guideline-directed
  • Patients with recurrent hyperkalemia
Request a rep visit
Acute vs. chronic management
Lokelma is for ongoing management of hyperkalemia. It should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset.
  • Designed for chronic, ongoing potassium control
  • Not for emergent, life-threatening hyperkalemia
  • Pairs with RAASi optimization over time
Get the clinical overview